Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Objective: To evaluate the effectiveness and safety of metformin use in clinical practice in a large sample of pharmacologically treated patients with type 2 diabetes and different levels of renal function. Design: Observational study between July 2004 and December 2010, mean follow-up 3.9 years. Setting: Hospital outpatient clinics and primary care in Sweden. Participants: 51 675 men and women with type 2 diabetes, registered in the Swedish National Diabetes Register, and on continuous glucose-lowering treatment with oral hypoglycaemic agents (OHAs) or insulin. Main outcome measures: Risks of cardiovascular disease (CVD), all-cause mortality and acidosis/serious infection, associated with each treatment regimens, were analysed in all patients and in subgroups with different estimated glomerular filtration rate (eGFR) intervals. Covariance adjustment and propensity scores were used to adjust for several baseline risk factors and characteristics at Cox regression. Results: Compared with metformin in monotherapy, HRs for fatal/non-fatal CVD and all-cause mortality with all other OHAs combined (approximately 80% sulphonylureas) in monotherapy were 1.02 (95% CI 0.93 to 1.12) and 1.13 (1.01 to 1.27), while 1.18 (1.07 to 1.29) and 1.34 (1.19 to 1.50) with insulin in monotherapy, adjusting using propensity scores. Metformin, compared with any other treatment, showed reduced risks of acidosis/serious infection (adjusted HR 0.85, 95% CI 0.74 to 0.97) and all-cause mortality (HR 0.87, 95% CI 0.77 to 0.99), in patients with eGFR 45–60 ml/min/1.73 m 2 , and no increased risks of all-cause mortality, acidosis/serious infection or CVD were found in patients with eGFR 30–45 ml/min/1.73 m 2 . Conclusions: Metformin showed lower risk than insulin for CVD and all-cause mortality and slightly lower risk for all-cause mortality compared with other OHA, in these 51 675 patients followed for 4 years. Patients with renal impairment showed no increased risk of CVD, all-cause mortality or acidosis/serious infection. In clinical practice, the benefits of metformin use clearly outbalance the risk of severe side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Concerns regarding lactic acidosis have not been substantiated.558,559”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [559]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The UKPDS demonstrated a reduction in all-cause mortality in the subgroup of obese DM2 patients treated with metformin compared with diet, SU or insulin,(2) also confirmed in a 10-year post-interventional follow-up.(3) Furthermore, several recent observational studies have reported reduced risk with metformin compared…”
ResultProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“Additional checks of the form of the time dependence were made using plots of scaled Schoenfeld residuals.(27) All statistical analyses were performed with SAS V.”
MethodGlobal and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“INTRODUCTION Type 2 diabetes mellitus (DM2) is a common disease, which causes major morbidity and mortality due to micro- and macrovascular complications.(1) A range of glucose-lowering To cite: Ekström N, Schiöler L, Svensson A-M, et al.”
BackgroundCardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A. M., & Pajak, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,263
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationMetformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658
“Similar treatment guidelines are endorsed by the Canadian Diabetes Association and the Australian Diabetes Society [62] and the results of numerous studies support this measured approach to the use of metformin in patients with moderate renal impairment [63,64].”
BackgroundMetformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA · doi:10.1001/jama.2014.15298 · Cited by 601
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Crowley, M. J., Diamantidis, C. J., McDuffie, J. R., Cameron, C. B., Stanifer, J. W., Mock, C. K., Wang, X., Tang, S., Nagi, A., Kosinski, A. S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1901 · Cited by 287
Yang, Q., Zheng, J., Chen, W., Chen, X., Wen, D., Chen, W., Xiong, X., & Zhang, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.640785 · Cited by 170
Scheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 174
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 193
Lazarus, B., Wu, A., Shin, J.-I., Sang, Y., Alexander, G. C., Secora, A., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 167
Eppenga, W. L., Lalmohamed, A., Geerts, A. F., Derijks, H. J., Wensing, M., Egberts, A., De Smet, P. A. G. M., & de Vries, F. (2014) · Diabetes Care · doi:10.2337/dc13-3023 · Cited by 169
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R., Hirshberg, B., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1850 · Cited by 163
Metformin and other antidiabetic agents in renal failure patients
Lalau, J., Arnouts, P., Sharif, A., & Broe, M. E. D. (2014) · Kidney International · doi:10.1038/ki.2014.19 · Cited by 159
Hung, S., Chang, Y., Liu, J., Kuo, K., Chen, Y., Hsu, C.-C., & Tarng, D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00123-0 · Cited by 153
Diabetes care – improvement through measurement
Eliasson, B., & Guðbjörnsdóttir, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(14)70732-6 · Cited by 142
Self-citationAkbari, A., Clase, C. M., Acott, P., Battistella, M., Bello, A. K., Feltmate, P., Grill, A. K., Karsanji, M., Komenda, P. V. J., Madore, F., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.013 · Cited by 149
Richy, F. F., Sabidó-Espin, M., Guedes, S., Corvino, F. A., & Gottwald-Hostalek, U. (2014) · Diabetes Care · doi:10.2337/dc14-0464 · Cited by 119
Mechanism and application of metformin in kidney diseases: An update
Song, A., Zhang, C., & Meng, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111454 · Cited by 130
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
Charytan, D. M., Solomon, S. D., Ivanovich, P., Remuzzi, G., Cooper, M. E., McGill, J. B., Parving, H., Parfrey, P., Singh, A. K., Burdmann, E. A., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13642 · Cited by 119
The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease
Kwon, S., Kim, Y. C., Park, J. Y., Lee, J., An, J. N., Kim, C. T., Oh, S., Park, S., Kim, D. K., Oh, Y. K., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0936 · Cited by 113
Metformin and metabolic diseases: a focus on hepatic aspects
Zheng, J., Woo, S., Hu, X., Botchlett, R. E., Chen, L., Huo, Y., & Wu, C. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0384-0 · Cited by 107
The Role and Mechanism of Metformin in Inflammatory Diseases
Lin, H., Ao, H., Guo, G., & Liu, M. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s436147 · Cited by 105
Ala, M., & Ala, M. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00167 · Cited by 95
Metformin: New Preparations and Nonglycemic Benefits
Fujita, Y., & Inagaki, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0829-8 · Cited by 98
Is metformin poised for a second career as an antimicrobial?
Malik, F. R., Mehdi, S. F., Ali, H., Patel, P., Basharat, A., Kumar, A., Ashok, F., Stein, J., Brima, W., Malhotra, P., et al. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2975 · Cited by 95
Bergmark, B. A., Bhatt, D. L., McGuire, D. K., Cahn, A., Mosenzon, O., Steg, P. G., Im, K., Kanevsky, E., Gurmu, Y., Raz, I., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040144 · Cited by 88
Rogacka, D., Audzeyenka, I., Rychłowski, M., Rachubik, P., Szrejder, M., Angielski, S., & Piwkowska, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.014 · Cited by 90
Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction
Varjabedian, L., Bourji, M., Pourafkari, L., & Nader, N. D. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0266-3 · Cited by 90
Biguanides: Species with versatile therapeutic applications
Kathuria, D., Raul, A. D., Wanjari, P. J., & Bharatam, P. V. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113378 · Cited by 96
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Du, Y., Zhu, Y., Zhou, Y., Ding, J., & Liu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00108-w · Cited by 96
Bell, S., Farran, B., McGurnaghan, S., McCrimmon, R. J., Leese, G. P., Petrie, J. R., McKeigue, P., Sattar, N., Wild, S., McKnight, J., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0579-5 · Cited by 84
Roumie, C. L., Chipman, J., Min, J. Y., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T., & Griffin, M. R. (2019) · JAMA · doi:10.1001/jama.2019.13206 · Cited by 76
Renoprotective Effects of Metformin
Broe, M. E. D., Kajbaf, F., & Lalau, J. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000481951 · Cited by 86
Zhang, K., Yang, W., Dai, H., & Deng, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108001 · Cited by 86
The right place for metformin today
Schernthaner, G., & Schernthaner, G.-H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107946 · Cited by 88
Type 2 diabetes and viral infection; cause and effect of disease
Wensveen, T. T., Gašparini, D., Rahelić, D., & Wensveen, F. M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108637 · Cited by 93
Neven, E., Vervaet, B. A., Brand, K. M. G., Gottwald‐Hostalek, U., Opdebeeck, B., Maré, A. D., Verhulst, A., Lalau, J., Kamel, S., Broe, M. E. D., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.027 · Cited by 84
Solini, A., Penno, G., Bonora, E., Fondelli, C., Orsi, E., Trevisan, R., Vedovato, M., Cavalot, F., Cignarelli, M., Morano, S., et al. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12381 · Cited by 74
Wemrell, M., Bennet, L., & Merlo, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000749 · Cited by 77
Connelly, P. J., Lonergan, M. E., Soto‐Pedre, E., Donnelly, L. A., Zhou, K., & Pearson, E. R. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12978 · Cited by 75
Metformin: A Candidate Drug for Renal Diseases
Corremans, R., Vervaet, B. A., D’Haese, P. C., Neven, E., & Verhulst, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010042 · Cited by 69
Pugliese, G., Solini, A., Bonora, E., Fondelli, C., Orsi, E., Nicolucci, A., & Penno, G. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.02.013 · Cited by 74
Significance of Metformin Use in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., & Tanabe, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124239 · Cited by 74
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases
Attallah, N., & Yassine, L. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.05.023 · Cited by 62
Risk of lactic acidosis in type 2 diabetes patients using metformin: A case control study
Aharaz, A., Pottegård, A., Henriksen, D. P., Hallas, J., Beck‐Nielsen, H., & Lassen, A. T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196122 · Cited by 68
Lee, O. Y. A., Wong, A. N. N., Ho, C. Y., Tse, K. W., Chan, A. Z., Leung, G., Kwan, Y. W., & Yeung, M. H. Y. (2024) · Antioxidants · doi:10.3390/antiox13060751 · Cited by 69
Metformin: Nonglycemic Effects and Potential Novel Indications
Anabtawi, A., & Miles, J. M. (2016) · Endocrine Practice · doi:10.4158/ep151145.ra · Cited by 65
Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
Vieira, I. H., Barros, L. M., Baptista, C. F., Rodrigues, D. M., & Paiva, I. (2021) · Clinical Diabetes · doi:10.2337/cd21-0043 · Cited by 63
Peter, W. L. S., Bzowyckyj, A. S., Anderson-Haag, T. L., Awdishu, L., Blackman, M., Bland, A., Chan, E., Chmielewski, C. M., Delgado, C., Eyler, R. F., et al. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae317 · Cited by 56
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Giaccari, A., Solini, A., Frontoni, S., & Prato, S. D. (2021) · Diabetes Care · doi:10.2337/dc20-1964 · Cited by 55
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Mor, A., Petersen, I., Sørensen, H. T., & Thomsen, R. W. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011523 · Cited by 50
Metformin lactic acidosis: Should we still be afraid?
Salvatore, T., Pafundi, P. C., Marfella, R., Sardu, C., Rinaldi, L., Monaco, L., Ricozzi, C., Imbriani, S., Nevola, R., Adinolfi, L. E., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107879 · Cited by 52
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
Self-citationManagement of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 51
Shih, C.-J., Wu, Y.-L., Chao, P.-W., Kuo, S., Yang, C., Li, S., Ou, S., & Chen, Y. (2015) · Scientific Reports · doi:10.1038/srep15260 · Cited by 47
Unleash Metformin: Reconsideration of the Contraindication in Patients with Renal Impairment
Lu, W. R., Defilippi, J., & Braun, A. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013505428 · Cited by 45
Rawshani, A., Svensson, A., Rosengren, A., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007599 · Cited by 43
Self-citationMetformin Use and Severe Dengue in Diabetic Adults
Htun, H. L., Yeo, T. W., Tam, C. C., Pang, J., Leo, Y., & Lye, D. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-21612-6 · Cited by 43
Metformin: time to review its role and safety in chronic kidney disease
Tanner, C., Wang, G., Liu, N., Andrikopoulos, S., Zajac, J. D., & Ekinci, E. I. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50239 · Cited by 48
Drug Therapies Affecting Renal Function: An Overview
Alhassani, R. Y., Bagadood, R. M., Balubaid, R. N., Barno, H. I., Alahmadi, M. O., & Ayoub, N. (2021) · Cureus · doi:10.7759/cureus.19924 · Cited by 48
Alhadramy, M. S. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.02.001 · Cited by 54
Vest, L. S., Koraishy, F. M., Zhang, Z., Lam, N. N., Schnitzler, M. A., Dharnidharka, V. R., Axelrod, D., Naik, A. S., Alhamad, T. A., Kasiske, B. L., et al. (2018) · Clinical Transplantation · doi:10.1111/ctr.13302 · Cited by 41
Hu, Y., Lei, M., Ke, G., Huang, X., Peng, X., Zhong, L., & Fu, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.559446 · Cited by 39
Metformin and the Liver: Unlocking the Full Therapeutic Potential
Perazza, F., Leoni, L., Colosimo, S., Musio, A., Bocedi, G., D’Avino, M., Agnelli, G., Nicastri, A., Rossetti, C., Sacilotto, F., et al. (2024) · Metabolites · doi:10.3390/metabo14040186 · Cited by 43
Thomsen, R. W., Baggesen, L. M., Svensson, E., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Johnsen, S. P. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12484 · Cited by 38
Optimal management of T2DM remains elusive
Holman, R. R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.243 · Cited by 38
Lochhead, P. J., Khalili, H., Sachs, M. C., Chan, A. T., Olén, O., & Ludvigsson, J. F. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa235 · Cited by 38
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
Targeting ageing and preventing organ degeneration with metformin
Sunjaya, A. P., & Sunjaya, A. F. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.009 · Cited by 37
How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sánchez-Fructuoso, A. I., de la Nieta, M. D. S., Agraz, I., & Soler, M. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112505 · Cited by 37
Adam, W. R., & O’Brien, R. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12515 · Cited by 34
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
“33 Furthermore, in individuals with an eGFR of 30-60 mL/min/1.73m 2 , careful sick-days education must be provided; metformin should be temporarily discontinued (i) before iodinated contrast imaging procedures 37 ; (ii) in the case of dehydration, because it may occur during severe vomiting, diarrhoea, fever, increase…”
InfluentialPusceddu, S., Vernieri, C., Prinzi, N., Torchio, M., Coppa, J. C., Antista, M., Niger, M., Milione, M., Giacomelli, L., Corti, F., et al. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820927271 · Cited by 33
Use of Metformin in Diseases of Aging
Miles, J. M., Rule, A. D., & Borlaug, B. A. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0490-4 · Cited by 34
Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist
Mariano, F., & Biancone, L. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00941-8 · Cited by 38
Marcum, Z. A., Forsberg, C. W., Moore, K. P., de Boer, I. H., Smith, N. L., Boyko, E. J., & Floyd, J. S. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4219-3 · Cited by 34
Bakris, G. L., & Molitch, M. E. (2016) · Diabetes Care · doi:10.2337/dc15-2534 · Cited by 33
Kiadaliri, A., Gerdtham, U., Nilsson, P. M., Eliasson, B., Guðbjörnsdóttir, S., & Carlsson, K. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062650 · Cited by 33
Self-citationChow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 35
Bertoluci, M. C., Salles, J. E. N., Silva‐Nunes, J., Pedrosa, H. C., Moreira, R. O., Duarte, R., Carvalho, D. M., Trujilho, F. R., Raposo, J. F. C. D. S., Parente, E. B., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00551-1 · Cited by 33
Rhee, C. M., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000450862 · Cited by 31
Dejager, S., Penfornis, A., Blickle, J., Fiquet, B., & Quéré, S. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s60312 · Cited by 31
Metformin in Peritoneal Dialysis: A Pilot Experience
Al-Hwiesh, A. K., Abdul‐Rahman, I. S., El-Din, M. A. N., Larbi, E., Divino‐Filho, J. C., Al-Mohanna, F. A.-A., & Gupta, K. L. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2013.00048 · Cited by 29
Agur, T., Steinmetz, T., Goldman, S. N., Zingerman, B. V., Bielopolski, D., Nesher, E., Fattal, I., Meisel, E., & Rozen‐Zvi, B. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02643-6 · Cited by 30
Lactate Levels with Chronic Metformin Use: A Narrative Review
Huang, W., Castelino, R. L., & Peterson, G. M. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0564-6 · Cited by 27
Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study
Zheng, J., Xie, S., Santoni, G., & Lagergren, J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0598-z · Cited by 28
Changes in metformin use in chronic kidney disease
Imam, T. H. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx017 · Cited by 30
Clemens, K. K., Liu, K., Shariff, S. Z., Schernthaner, G., Tangri, N., & Garg, A. X. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12658 · Cited by 29
Metformin Use and Metformin-associated Lactic Acidosis in Intensive Care Unit Patients with Diabetes
Rajasurya, V., Anjum, H., & Surani, S. (2019) · Cureus · doi:10.7759/cureus.4739 · Cited by 29
Ekström, N., Svensson, A., Miftaraj, M., Sundell, K. A., Cederholm, J., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000059 · Cited by 25
Self-citationObesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation
Martín-Moreno, P. L., Shin, H. S., & Chandraker, A. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112497 · Cited by 25
Safety and effectiveness of metformin in patients with reduced renal function: a systematic review
Orloff, J., Min, J. Y., Mushlin, A., & Flory, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14440 · Cited by 24
Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to?
Huang, W., Castelino, R. L., & Peterson, G. M. (2014) · Internal Medicine Journal · doi:10.1111/imj.12369 · Cited by 26
Complex interplay between metformin, AKI and lactic acidosis
Rhee, C. M., & Kalantar‐Zadeh, K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.105 · Cited by 24
Karlsson, S. A., Hero, C., Svensson, A., Franzén, S., Miftaraj, M., Guðbjörnsdóttir, S., Eeg‐Olofsson, K., Eliasson, B., & Sundell, K. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020309 · Cited by 24
Self-citationGor, D., Gerber, B. S., Walton, S. M., Lee, T. A., Nutescu, E. A., & Touchette, D. R. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.13003 · Cited by 25
Piwkowska, A., Rogacka, D., Jankowski, M., & Angielski, S. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_2028 · Cited by 25
Genetic architecture of human fibrotic diseases: disease risk and disease progression
Gardet, A., Zheng, T. S., & Viney, J. L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00159 · Cited by 24
Racial Concordance and the Quality of Medical Care: Evidence from the Military
Frakes, M., & B, J. G. A. (2022) · National Bureau of Economic Research · doi:10.3386/w30767 · Cited by 33
Does metformin do more benefit or harm in chronic kidney disease patients?
Broe, M. E. D., & Jouret, F. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.059 · Cited by 23
Metadata
- Authors
- Ekström, N., Schiöler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., & Gudbjörnsdottir, S.
- Affiliations
- University of Gothenburg (SE)
- Region Västra Götaland (SE)
- Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Centre of Registers in Region Västra Götaland, Gothenburg, Sweden
- Uppsala University (SE)
- Corresponding author
- Ekström, Nils
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2012
- Volume
- 2
- Issue
- 4
- Pages
- e001076
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3400073
- OpenAlex
- W2167639134
- Cited by
- 221
- References
- 39
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 19 · 2018: 13 · 2017: 26 · 2016: 18 · 2015: 18 · 2014: 29 · 2013: 13
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sveriges Kommuner och Landsting
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes, renal function, estimated glomerular filtration rate, cardiovascular disease, all-cause mortality, lactic acidosis, serious infections, sulfonylureas, insulin monotherapy, oral antidiabetic drugs, drug safety, treatment effectiveness, Swedish National Diabetes Register, propensity score adjustment, real-world clinical practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
